Extended release delivery of erlotinib glutathione nanosponge for targeting lung cancer

References

• He Y, Su Z, Xue L, et al. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy. J Controlled Release. 2016;229:89–92.
   Web of Science ®Google Scholar
• Kim ST, Lee J, Kim JH, et al. Comparison of gefitinib versus erlotinib in patients with nonsmall cell lung cancer who failed previous chemotherapy. Cancer. 2010;116:3025–3033.
   PubMed Web of Science ®Google Scholar
• Wang Y, Schmid-bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol. 2011;4:19–29.
   Web of Science ®Google Scholar
• Nawaz K, Webster RM. The non-small-cell lung cancer drug market. Nat Rev Drug Discov. 2016;15:229–230.
   PubMed Web of Science ®Google Scholar
• Mandal B, Mittal NK, Balabathula P, et al. Development and in vitro evaluation of core–shell type lipid–polymer hybrid nanoparticles for the delivery of erlotinib in non-small cell lung cancer. Financial Res Lett. 2015;81:162–171.
   Google Scholar
• Sechler M, Cizmic AD, Avasarala S, et al. Non-small-cell lung cancer: molecular targeted therapy and personalized medicine: drug resistance, mechanisms, and strategies. Pharmgenom Pers Med. 2013;6:25–36.
   PubMedGoogle Scholar
• Qi W, Cooke LS, Stejskal A, et al. MP470, a novel receptor tyrosine kinase inhibitor, in combination with Erlotinib inhibits the HER family/PI3K/Akt pathway and tumour growth in prostate cancer. BMC Cancer. 2009;9:142.
   PubMed Web of Science ®Google Scholar
• Dora CP, Trotta F, Kushwah V, et al. Potential of erlotinib cyclodextrin nanosponge complex to enhance solubility, dissolution rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym. 2015;137:339–349.
   PubMed Web of Science ®Google Scholar
• Dowell J, Minna JD, Kirkpatrick P. Erlotinib hydrochloride. Nat Rev Drug Discov. 2005;4:13–14.
   PubMed Web of Science ®Google Scholar
• Liversidge G, Jenkins S. Nanoparticulate erlotinib formulations. EP 1871345 B1; 2012.
   Google Scholar
• Yang KM, Shin IC, Park JW, et al. Nanoparticulation improves bioavailability of erlotinib. Drug Develop Indus Pharm. 2017;43:1557–1565.
   PubMed Web of Science ®Google Scholar
• Vrignaud S, Hureaux J, Wack S, et al. Design, optimization and in vitro evaluation of reverse micelle-loaded lipid nanocarriers containing erlotinib hydrochloride. Int J Pharm. 2012;436:194–200.
   PubMed Web of Science ®Google Scholar
• Parthasaradhi RB, Rathnakar RK, Raji RR, et al. Erlotinib hydrochloride polymorph Form A substantially free of polymorph Form. B. EP221873A1; 2010.
   Google Scholar
• Cui Y, Dong H, Cai X, et al. Mesoporous silica nanoparticles capped with disulfide-linked PEG gatekeepers for glutathione-mediated controlled release. ACS Appl Mater Interfaces. 2012;4:3177–3183.
   PubMed Web of Science ®Google Scholar
• Shepherd FA, Pereira JR, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123–132.
   PubMed Web of Science ®Google Scholar
• Darandale SS, Vavia PR. Cyclodextrin-based nanosponges of curcumin: formulation and physicochemical characterization. J Incl Phenom Macrocycl Chem. 2013;75:315–322.
   Web of Science ®Google Scholar
• Sherje AP, Darvyaker BR, Kadam D, et al. Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym. 2017;173:37–49.
   PubMed Web of Science ®Google Scholar
• Caldera F, Tannous M, Cavalli R, et al. Evolution of cyclodextrin nanosponges. Int J Pharm. 2017. Doi: 10.1016/j.ijpharm.2017.06.072
   PubMedGoogle Scholar
• Swaminathan S, Cavalli R, Trotta F. Cyclodextrin-based nanosponges: a versatile platform for cancer nanotherapeutics development. WIREs Nanomed Nanobiotechnol. 2016;8:579–601.
   PubMed Web of Science ®Google Scholar
• Yang X, He D, He X, et al. Glutathione-mediated degradation of surface-capped MnO 2 for drug release from mesoporous silica nanoparticles to cancer cells. Part Part Syst Charact. 2015;32:205–212.
   Web of Science ®Google Scholar
• Wu G, Fang Y, Yang S, et al. Glutathione metabolism and its implications for health. J Nutr. 2004;134:489–492.
   PubMed Web of Science ®Google Scholar
• Daga M, Ulllio C, Argenziano M, et al. GSH-targeted nanosponges increase doxorubicin induced toxicity ‘in vitro’ and ‘in vivo’ in cancer cells with high antioxidant defences. Free Rad Biol Med. 2016;97:24–37.
   PubMed Web of Science ®Google Scholar
• Anajafi T, Mallik S. Polymersome-based drug-delivery strategies for cancer therapeutics. Ther Deliv. 2015;6:521–534.
   PubMed Web of Science ®Google Scholar
• Xu Z, Wang D, Xu S, et al. Preparation of a camptothecin prodrug with glutathione-responsive disulfide linker for anticancer drug delivery. Chem Asian J. 2014;9:199–205.
   PubMed Web of Science ®Google Scholar
• Wang J, Sun X, Mao W, et al. Tumour redox heterogeneity-responsive prodrug nanocapsules for cancer chemotherapy. Adv Mater. 2013;25:3670–3676.
   PubMed Web of Science ®Google Scholar
• Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. Nat Rev Drug Discov. 2010;9:615–627.
   PubMed Web of Science ®Google Scholar
• Trotta F, Caldera F, Dianzani C, et al. Glutathione bioresponsive cyclodextrin nanosponges. Chempluschem. 2016;81:439–443.
   PubMed Web of Science ®Google Scholar
• Shende PK, Gaud RS, Bakal R, et al. Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrin-based nanosponges on solubility, in vitro release and stability studies. Colloids Surfaces B Biointerfaces. 2015;136:105–110.
   PubMed Web of Science ®Google Scholar
• Hariri G, Edwards AD, Merrill TB, et al. Sequential targeted delivery of paclitaxel and camptothecin using a cross-linked ‘nanosponge’ network for lung cancer chemotherapy. Mol Pharmaceutics. 2014;11:265–275.
   PubMed Web of Science ®Google Scholar
• Jiang Y, Yang N, Zhang H, et al. Enhanced in vivo antitumour efficacy of dual-functional peptide-modified docetaxel nanoparticles through tumour targeting and Hsp90 inhibition. J Control Release. 2016;221:26–36.
   PubMed Web of Science ®Google Scholar
• Ernsting MJ, Tang W, Maccallum NW, et al. Preclinical pharmacokinetic, biodistribution, and anti-cancer efficacy studies of a docetaxel-carboxymethylcellulose nanoparticle in mouse models. Biomaterials. 2012;33:1445–1454.
   PubMed Web of Science ®Google Scholar
• Alexis F, Pridgen E, Molnar LK, et al. Factors affecting the clearance and biodistribution of polymeric nanoparticles. Mol Pharm. 2008;5:505–515.
   PubMed Web of Science ®Google Scholar
• Mailänder V, Landfester K. Interaction of nanoparticles with cells. Biomacromolecules. 2009;10:2379–2400.
   PubMed Web of Science ®Google Scholar
• Shandiz SAS, Ardestani AS, Shahbazzadeh D, et al. Novel imatinib-loaded silver nanoparticles for enhanced apoptosis of human breast cancer MCF-7 cells. Artif Cells Nanomed Biotechnol. 2017;45:1–10.
   Web of Science ®Google Scholar
• Mehdizadeh M, Rouhani H, Sepehri N, et al. Biotin decorated PLGA nanoparticles containing SN-38 designed for cancer therapy. Artif Cells Nanomed Biotechnol. 2016;45:495–504.
   PubMed Web of Science ®Google Scholar
• Cho EC, Xie J, Wurm PA, et al. Understanding the role of surface charges in cellular adsorption versus internalization by selectively removing gold nanoparticles on the cell surface with a I2/KI etchant. Nano Lett. 2009;9:1080–1084.
   PubMed Web of Science ®Google Scholar
• Xiao W, Chen W-H, Xu X-D, et al. Design of a cellular-uptake-shielding plug and play template for photo controllable drug release. Adv Mater Weinheim. 2011;23:3526–3530.
   PubMed Web of Science ®Google Scholar
• Perrault SD, Walkey C, Jennings T, et al. Mediating tumour targeting efficiency of nanoparticles through design. Nano Lett. 2009;9:1909–1915.
   PubMed Web of Science ®Google Scholar